MUM1/IRF4 expression in the circulating compartment of chronic lymphocytic leukemia

References

• Hans C P, Weisenburger D D, Greiner T C, Gascoyne R D, Delabie J, Ott G, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103: 275–282
   PubMed Web of Science ®Google Scholar
• Alizadeh A A, Eisen M B, Davis R E, Ma C, Lossos I S, Rosenwald A, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403: 503–511
   PubMed Web of Science ®Google Scholar
• Falini B, Fizzotti M, Pucciarini A, Bigerna B, Marafioti T, Gambacorta M, et al. A monoclonal antibody (MUM1p) detects expression of the MUM1/IRF4 protein in a subset of germinal center B cells, plasma cells, and activated T cells. Blood 2000; 95: 2084–2092
   PubMed Web of Science ®Google Scholar
• Tsuboi K, Iida S, Inagaki H, Kato M, Hayami Y, Hanamura I, et al. MUM1/IRF4 expression as a frequent event in mature lymphoid malignancies. Leukemia 2000; 14: 449–456
   PubMed Web of Science ®Google Scholar
• Chang C C, Lorek J, Sabath D E, Li Y, Chitambar C R, Logan B, et al. Expression of MUM1/IRF4 correlates with clinical outcome in patients with B-cell chronic lymphocytic leukemia. Blood 2002; 100: 4671–4675
   PubMed Web of Science ®Google Scholar
• Ito M, Iida S, Inagaki H, Tsuboi K, Komatsu H, Yamaguchi M, et al. MUM1/IRF4 expression is an unfavorable prognostic factor in B-cell chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Jpn J Cancer Res 2002; 93: 685–694
   PubMedGoogle Scholar
• Soma L A, Craig F E, Swerdlow S H. The proliferation center microenvironment and prognostic markers in chronic lymphocytic leukemia/small lymphocytic lymphoma. Hum Pathol 2006; 37: 152–159
   PubMed Web of Science ®Google Scholar
• Chen C C, Raikow R B, Sonmez-Alpan E, Swerdlow S H. Classification of small B-cell lymphoid neoplasms using a paraffin section immunohistochemical panel. Appl Immunohistochem Mol Morphol 2000; 8: 1–11
   PubMedGoogle Scholar
• Li A H, Rosenquist R, Forestier E, Holmberg D, Lindh J, Lofvenberg E, et al. Clonal rearrangements in childhood and adult precursor B acute lymphoblastic leukemia: a comparative polymerase chain reaction study using multiple sets of primers. Eur J Haematol 1999; 63(4)211–218
   PubMed Web of Science ®Google Scholar
• Melan M, Foon K A, Marks S M, Kant J A. Immunoglobulin heavy chain (IgH) gene somatic hypermutation status using homoduplex-separated RT-PCR products. Blood 2004; 194, abstract 4813
   Google Scholar
• Damle R N, Wasil T, Fais F, Ghiotto F, Valetto A, Allen S L, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999; 94: 1840–1847
   PubMed Web of Science ®Google Scholar
• Wiestner A, Rosenwald A, Barry T S, Wright G, Davis R E, Henrickson S E, et al. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood 2003; 101: 4944–4951
   PubMed Web of Science ®Google Scholar
• Crespo M, Bosch F, Villamor N, Bellosillo B, Colomer D, Rozman M, et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 2003; 348: 1764–1775
   PubMed Web of Science ®Google Scholar
• Rassenti L Z, Huynh L, Toy T L, Chen L, Keating M J, Gribben J G, et al. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med 2004; 351: 893–901
   PubMed Web of Science ®Google Scholar
• Stevenson F K, Caligaris-Cappio F. Chronic lymphocytic leukemia: revelations from the B-cell receptor. Blood 2004; 103: 4389–4395
   PubMed Web of Science ®Google Scholar
• Ferrarini M, Chiorazzi N. Recent advances in the molecular biology and immunobiology of chronic lymphocytic leukemia. Semin Hematol 2004; 41: 207–223
   PubMed Web of Science ®Google Scholar
• Deaglio S, Capobianco A, Bergui L, Durig J, Morabito F, Duhrsen U, et al. CD38 is a signaling molecule in B-cell chronic lymphocytic leukemia cells. Blood 2003; 102: 2146–2155
   PubMed Web of Science ®Google Scholar
• Chen L, Apgar J, Huynh L, Dicker F, Giago-McGahan T, Rassenti L, et al. ZAP-70 directly enhances IgM signaling in chronic lymphocytic leukemia. Blood 2005; 105: 2036–2041
   PubMed Web of Science ®Google Scholar
• Pernis A B. The role of IRF-4 in B and T cell activation and differentiation. J Interferon Cytokine Res 2002; 22: 111–120
   PubMed Web of Science ®Google Scholar
• Gupta S, Jiang M, Anthony A, Pernis A B. Lineage-specific modulation of interleukin 4 signaling by interferon regulatory factor 4. J Exp Med 1999; 190: 1837–1848
   PubMed Web of Science ®Google Scholar
• Glynne R, Ghandour G, Rayner J, Mack D H, Goodnow C C. B-lymphocyte quiescence, tolerance and activation as viewed by global gene expression profiling on microarrays. Immunol Rev 2000; 176: 216–246
   PubMed Web of Science ®Google Scholar
• Klein U, Casola S, Cattoretti G, Shen Q, Lia M, Mo T, et al. Transcription factor IRF4 controls plasma cell differentiation and class-switch recombination. Nat Immunol 2006; 7: 773–782
   PubMed Web of Science ®Google Scholar
• Uranishi M, Iida S, Sanda T, Ishida T, Tajima E, Ito M, et al. Multiple myeloma oncogene 1 (MUM1)/interferon regulatory factor 4 (IRF4) upregulates monokine induced by interferon-gamma (MIG) gene expression in B-cell malignancy. Leukemia 2005; 19: 1471–1478
   PubMed Web of Science ®Google Scholar
• Jones D, Benjamin R J, Shahsafaei A, Dorfman D M. The chemokine receptor CXCR3 is expressed in a subset of B-cell lymphomas and is a marker of B-cell chronic lymphocytic leukemia. Blood 2000; 95: 627–632
   PubMed Web of Science ®Google Scholar
• Ghia P, Guida G, Stella S, Gottardi D, Geuna M, Strola G, et al. The pattern of CD38 expression defines a distinct subset of chronic lymphocytic leukemia (CLL) patients at risk of disease progression. Blood 2003; 101: 1262–1269
   PubMed Web of Science ®Google Scholar
• Hamblin T. Chronic lymphocytic leukaemia: one disease or two?. Ann Hematol 2002; 81: 299–303
   PubMed Web of Science ®Google Scholar
• Orchard J A, Ibbotson R E, Davis Z, Wiestner A, Rosenwald A, Thomas P W, et al. ZAP-70 expression and prognosis in chronic lymphocytic leukaemia. Lancet 2004; 363: 105–111
   PubMed Web of Science ®Google Scholar
• Hamblin T J, Orchard J A, Ibbotson R E, Davis Z, Thomas P W, Stevenson F K, et al. CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease. Blood 2002; 99: 1023–1029
   PubMed Web of Science ®Google Scholar
• Schroers R, Griesinger F, Trumper L, Haase D, Kulle B, Klein-Hitpass L, et al. Combined analysis of ZAP-70 and CD38 expression as a predictor of disease progression in B-cell chronic lymphocytic leukemia. Leukemia 2005; 19: 750–758
   PubMed Web of Science ®Google Scholar
• Ibrahim S, Keating M, Do K A, O'Brien S, Huh Y O, Jilani I, et al. CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia. Blood 2001; 98: 181–186
   PubMed Web of Science ®Google Scholar
• Chevallier P, Penther D, Avet-Loiseau H, Robillard N, Ifrah N, Mahe B, et al. CD38 expression and secondary 17p deletion are important prognostic factors in chronic lymphocytic leukaemia. Br J Haematol 2002; 116: 142–150
   PubMed Web of Science ®Google Scholar
• Krober A, Seiler T, Benner A, Bullinger L, Bruckle E, Lichter P, et al. V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood 2002; 100: 1410–1416
   PubMed Web of Science ®Google Scholar
• Damle R N, Allen S L, Rai K R, Chiorazzi N. CD38 expression identifies an active subset of proliferating cells within the clonal population in chronic lymphocytic leukemia patients (in vitro analysis). Blood (Suppl.) 2006; 108: 28
   PubMed Web of Science ®Google Scholar